Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Presidential Symposium 3

4332 - Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial


10 Oct 2016


Presidential Symposium 3


Alessandro Gronchi


Annals of Oncology (2016) 27 (6): 1-36. 10.1093/annonc/mdw435


A. Gronchi1, S. Ferrari2, V. Quagliuolo3, J. Martin Broto4, A. Lopez-Pousa5, G. Grignani6, V. Ferraresi7, J. Blay8, P. Rutkowski9, F.D. Merlo10, E. Marchesi11, P. Ledesma12, A.P. Dei Tos13, S. Bague Rosell14, J. Coindre15, C. Morosi16, S. Stacchiotti17, P. Picci18, P. Bruzzi19, P.G. Casali20

Author affiliations

  • 1 Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milano/IT
  • 2 Medical Oncology, Istituto Ortopedico Rizzoli, Bologna/IT
  • 3 Surgery, Istituto Clinico Humanitas, Rozzano/IT
  • 4 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 5 Research, Hospital de la Santa Creu i Sant Pau, Barcelona/ES
  • 6 Medical Oncology, Istituto di Candiolo-IRCCS-Fondazione Piemontese per la Ricerca sul Cancro-Onlus, Candiolo/IT
  • 7 Istituti Fisioterapici Ospedalieri, U.o. Oncologia Medica 1, Regina Elena National Cancer Institute, 144 - Roma/IT
  • 8 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 9 Soft Tissue/bone Sarcoma And Melanoma, MSC Memorial Cancer Centre and Institute Maria Sklodowska-Curie, 02781 - Warsaw/PL
  • 10 Biostatistics, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova/IT
  • 11 Laboratorio Di Oncologia Sperimentale, Istituto Ortopedico Rizzoli, 40136 - Bologna/IT
  • 12 None, Sofpromed Investigacion Clinica, Palma de Mallorca/ES
  • 13 Department Of Pathology, Ospedale Regionale Ca' Foncello, 31100 - Treviso/IT
  • 14 Department Of Pathology, Hospital de la Santa Creu i Sant Pau, 08026 - Barcelona/ES
  • 15 Pathology, Institute Bergonié, 33076 - Bordeaux/FR
  • 16 Radiology, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 17 Department Of Cancer Medicine, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano/IT
  • 18 Muscoloskeletal Oncology, Istituto Ortopedico Rizzoli, Bologna/IT
  • 19 Epidemiology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova/IT
  • 20 Adult Sarcoma Medical Oncology Unit, Istituto Nazionale Tumori, Milano/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4332


An Italian Sarcoma Group randomized trial versus no chemotherapy was indicative of an OS benefit with 5 cycles of adjuvant full-dose epirubicin + ifosfamide in localized high-risk STS (JCO 2001;19:1238). A subsequent randomized trial showed no difference between 3 vs 5 cycles of the same neo-adjuvant regimen (JCO 2012;30:850).


This multicenter European randomized trial compared epirubicin 120 mg/sqm + ifosfamide 9 g/sqm versus an histology-driven regimen: gemcitabine + docetaxel in undifferentiated pleomorphic sarcoma (UPS); trabectedin in high-grade myxoid liposarcoma; high-dose prolonged-infusion ifosfamide in synovial sarcoma (SS); etoposide + ifosfamide in malignant peripheral nerve sheath tumors (MPNST); gemcitabine + dacarbazine in leiomyosarcoma (LMS). Patients had localized high-risk STS (grade = 3; size >5 cm; deep site) of extremities or trunk wall. Primary end-point was RFS. With an expected accrual of 350 randomized patients, the trial was powered to show a 1/3 reduction in the hazard risk of relapse in favor of histology-driven therapy (with 80% power at the 5% [1-sided] significance level). Yearly futility analyses were conducted.


From May 2011 to May 2016, 287 patients were randomized (97 = UPS; 65 = myxoid liposarcoma; 70 = SS; 27 = MPNST; 28 = LMS). At the third futility analysis, with a median follow-up of 12.3 months, the RFS probability at 46 months was 0.62 and 0.38 (log rank p = 0.004; figure 1) and OS probability at 46 months was 0.89 and 0.64 (log rank p = 0.033; figure 2), in the standard and in the histology-driven arm, respectively. In agreement with the Independent Reviewing Committee, the study was closed in advance. The analysis is being updated and subgroup analyses will be reported.


This trial provides randomized evidence that a neo-adjuvant chemotherapy with 3 full-dose courses of an anthracycline plus ifosfamide full-dose regimen can be associated with an absolute benefit averaging 20% for both RFS and OS over a different chemotherapy regimen, in a population of STS patients selected by a risk of relapse averaging 60-70%.

Clinical trial identification

NCT01710176; EUDRACT 2010 – 023484 – 17

Legal entity responsible for the study

Italian Sarcoma Group


Eurosarc FP7 278472


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings